Hyperhomocystinemia as a thrombotic risk factor in patients sufferlng from systemic Lupus Erithematosus and antiphospholipid syndrome

Abstract

Objectives: to detect the prevalence of hyperhcy in SLE patients with and without antiphospholipid syndrom; to compare the Hcy leveis between those patients and healthy controis and to determine the correlation between hyperhcy and antiphospholipid antibodies. Patients and methods: we studied 44 SLE patients: 17 had antiphospholipid syndroni and 27 didn't have it, and we compared them to 24 healthy controis. Ah of them where checked clinically and with laboratory tests like anticardiolypin antibodies, lupus anticoagulant and Hcy. Hcy > 9 was considered abnormal. Patient who had hyperhcy were treated with folie acid+vitD6+vitB12 a month along. Statistical analysis: cualytative variables: chi square or Flscher's; cuantitative variables: Student's T test or Mann-Whitney's test. Results and conclutions: there were 35 trombotic inanifestations in 44 patients. Hyperhcy was present in 27 SLE patients (61,4%), 12 of them had antiphospholipid syndrom. Hcy concentrations patients Vs. controls was statisticaly different (p=0,002). There was also stastisticaly different the hcy concentration from SLE patients with SAF VS controls (p=0,003) and without SAF VS controis (p= 0,015). From 33 SLE patients, 20(33%) were aCL(+). 15(75%) of them had hiperhcy.